ClinicalTrials.gg
CompletedNCT03526133Updated Sep 30, 2019

Validation of Sleep Apnea Diagnosis Device

An observational study in Sleep Apnea, sponsored by University of Sao Paulo General Hospital. Completed at 1 site in Brazil. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-09-30.

Sponsored by University of Sao Paulo General Hospital · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
300
Ages
18 Years to 80 Years
Sex
All
01

Study summary

Obstructive sleep apnea (OSA) is common and largely underdiagnosed disease. The standard method for the diagnosis of OSA is a complete night polysomnography (PSG). Simple methods for OSA diagnosis are necessary. The overnight oximetry with the oxygen desaturation index (ODI) has been largely investigated as a diagnostic test for OSA but its accuracy remains undefined. The aim of our study is to evaluate if an wireless polygraph (Oxistar) is accurate to diagnosis OSA in patients referred to a Sleep Lab.

Read the detailed description

Consecutive patients referred to the sleep laboratory with suspected diagnosis of OSA underwent in-laboratory polysomnography (PSG) and simultaneously wireless polygraph. The PSG oximeter and the wireless polygraph were worn on different fingers of the same hand. All sleep studies were reviewed by one blind investigator according the 2017 American Academy of Sleep Medicine recommendations. The number of desaturations from wireless polygraph at the 3 predefined threshold levels (of ODI-2%, ODI-3%, or ODI-4%) was derived automatically using proprietary algorithm. Moderate to severe OSA was defined as AHI ≥ 15 events/h. The diagnostic accuracy of ODI-2%, 3%, and 4% for the diagnosis of moderate-severe OSA were calculated for cut-off values from 1 to 20 desaturation events/h. The sleep actimetry was compared with the sleep stages from PSG, most of the statistical metrics applied for diagnosis were used to evaluate the applicability of this proposed method. Finally, the snoring events computed by the smartphone application were compared with the events heard by a specialist and the statistical comparison metrics were evaluated.

02

Conditions studied

  • Sleep Apnea

Keywords

  • sleep apnea
  • polygraph
  • home sleep apnea test (HSAT)
  • apnea hypopnea index (AHI)
  • oxygen desaturation index (ODI)
  • portable monitor
  • sleep actimetry
  • snoring
03

In context

Sleep Apnea Syndromes

2,183 studies on the registry are indexed under Sleep Apnea Syndromes; 284 are open to participants now.

This study's enrollment of 300 is above the median of 109 across 659 observational studies indexed under Sleep Apnea Syndromes.

Browse Sleep Apnea Syndromes studies →

Lead sponsor

University of Sao Paulo General Hospital is the lead sponsor of 608 studies on the registry; 97 are open to participants now.

Of its 8 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Consecutive patients referred to a university-based tertiary sleep referral centre.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • referred by medical staff for an overnight assessment for suspected sleep apnea

Exclusion criteria

Exclusion Criteria:

  • polysomnography for the CPAP titration
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
300 participants (actual)
Patient registry
No

Interventions

  • Diagnostic testPolysomnography (PSG) and wireless sensor Oxistar

    Monitoring the apnea-hypopnea index (AHI) derived from PSG and the oxygen desaturation index (ODI) obtained by the Oxistar.

06

What researchers measure

Primary outcomes

  1. Sensitivity

    Sensitivity of Oxistar device to detect apnea events compared to gold-standard polysomnography

    Time frame: Night during the polysomnography exam

  2. Specificity

    Specificity of Oxistar device to detect apnea events compared to gold-standard polysomnography

    Time frame: Night during the polysomnography exam

  3. Area under the curve (AUC)

    AUC from ROC curves reflects the accuracy of Oxistar device to detect apnea events compared to gold-standard polysomnography

    Time frame: Night during the polysomnography exam

  4. Bland-Altman Graph

    The Bland-Altman graph evaluates the "agreement" between the gold-standard polysomnography and Oxistar device

    Time frame: Night during the polysomnography exam

  5. Interclass Correlation Coefficient (ICC)

    ICC measures the reliability of measurements or ratings between the gold-standard polysomnography and Oxistar device

    Time frame: Night during the polysomnography exam

Secondary outcomes

  1. Sleep Actigraphy

    Actigraphy is the continuous measurement of activity or movement with the use of a small device called an actigraph. Periods of movement suggest wakefulness while those of relative stillness would likely correspond to sleep or quiescence. The Oxistar has a embeded actigraph whose data will be compared with the sleep stage scoring from polysomnography (PSG), the gold standard for sleep assessment. Epoch-by-epoch (30 seconds) agreement between the actigraph and PSG will be assessed by calculating sensitivity, specificity, accuracy, area under the curve (AUC), Bland-Altman graph and interclass correlation coefficient (ICC)

    Time frame: Night during the polysomnography exam

  2. Number of snoring events per hour of register (snoring/h)

    Snoring is one of the signs suggestive of obstructive sleep apnea and has recently been considered as having great diagnostic potential. The smartphone application (app) through microphone performs the recording and the characteristics extraction of the patient's audio during sleep (register time). A multilayer perceptron (MPL) neural network classifies the event as snoring or non-snoring. Lastly, the amount of snoring occured is accounted and divided by the register time leading to the number of snoring/h. The agreement between snoring/h measured by the app and the heard by a specialist will be assessed by calculating sensitivity, specificity, accuracy and area under the curve (AUC).

    Time frame: Night during the polysomnography exam

07

Study locations

1 site
  • Incor - Heart Institute, Sleep Laboratory
    São Paulo, 05403-900, Brazil
08

References and documents

Publications

  • Pinheiro GDL, Cruz AF, Domingues DM, Genta PR, Drager LF, Strollo PJ, Lorenzi-Filho G. Validation of an Overnight Wireless High-Resolution Oximeter plus Cloud-Based Algorithm for the Diagnosis of Obstructive Sleep Apnea. Clinics (Sao Paulo). 2020 Nov 27;75:e2414. doi: 10.6061/clinics/2020/e2414. eCollection 2020. PubMed 33263626 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 30, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03526133
Collaborators
Biologix Sistemas Ltda
Responsible party
Sponsor
First posted
May 16, 2018
Start date
Jul 7, 2017
Primary completion
Dec 7, 2018
Completion
Feb 7, 2019
Last update
Sep 30, 2019

Study contacts

Geraldo Lorenzi-Filho, MD, PhD
principal investigator · Associate Professor

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion